HCV - Indenix is Nearing Phase III for Valopicitabine

Indenix is Nearing Phase III for Valopicitabine
It is always good to see progress with alternatives to current medical therapy for HCV. Even though companies that are working on solutions to be used with interferon are not really offering anything groundbreaking or revolutionary, it does continue the...

Pill Form of Therapy for HCV Coming Closer
This report is an update of therapy progress presented at the AASLD (American Academy for the Study of Liver Diseases). Three separate approaches are covered. Yes, progress is being made....

Vertex Progresses with VX-950
Vertex is the racehorse to watch right now. They are progressing quicky on their preliminary good results. While it's not yet time to line up for their treatment, we believe theirs will be first to market of the new approaches...

Conclusions About Milk Thistle
A May 2005 review of clinical studies which casts doubt on milk thistle's value has recently been re-released into the press. Alternatively, an extensive amount of research supports the continued usage of this herb at higher dosages. Researchers of the...

Shorter Therapy Effective for Genotypes 2 and 3
Genotypes 2 and 3 are much more responsive to current interferon combination therapies. This report details studies that show a shorter course of treatment might be just as effective as longer courses. Researchers continue to refine treatment protocols for HCV...